Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$3.75 USD
+0.52 (16.10%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $3.80 +0.05 (1.33%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Pyxis Oncology, Inc. [PYXS]
Reports for Purchase
Showing records 1 - 5 ( 5 total )
Company: Pyxis Oncology, Inc.
Industry: Medical - Drugs
Awaiting Initial Clinical Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pyxis Oncology, Inc.
Industry: Medical - Drugs
PYX-201 Progresses With Initial Data Expected in the Fall; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pyxis Oncology, Inc.
Industry: Medical - Drugs
Preclinical Data Update Support Safety and Broad Efficacy Potential of PYX-201 as an ADC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pyxis Oncology, Inc.
Industry: Medical - Drugs
PYX-201 Showed Signs of a Differentiated Safety Profile as an ADC; New PT $7; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pyxis Oncology, Inc.
Industry: Medical - Drugs
|